Supply of biological medicines
Original notice title
Spain – Antineoplastic and immunomodulating agents – Suministro sucesivo de diversos medicamentos biológicos cuya administración se realiza en los hospitales de día de los centros hospitalarios del Servicio Gallego de Salud.
Opportunity Score
Why this score?
Opportunity
70 / 100
Complexity
60 / 100
Risk factors
The structured data shows only one award criterion per lot, while the XML notice suggests all three criteria (technical...
Structured data marks 'isEuFunded: true', but the XML notice says 'FundingProgramCode: no-eu-funds'. This may affect co...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- EUR 54M estimated value
- Supplies contract
- 3 lots
- Duration 2 YEAR
- Successive supply of 8 biological drugs (intravenous) for day hospitals of SERGAS in Santiago de Compostela
- Each lot corresponds to a specific drug: Bevacizumab, Eculizumab, Infliximab, Natalizumab, Rituximab, Tocilizumab, Trastuzumab, Ustekinumab
Show full summary
This open tender by SERGAS (Galician Health Service) seeks the successive supply of 8 biological drugs (intravenous administration) for day hospitals in Santiago de Compostela, Spain. The contract is divided into 8 lots, each for a specific drug, with a total estimated value of €54,036,507 EUR. Duration is 2 years. The deadline for submission is 20 August 2026. The procedure is open and electronic submission is required. Award criteria vary by lot, with a mix of price, technical quality, and environmental criteria. The notice is EU-funded per structured data, but the XML notice indicates no EU funds. Procurement documents were not analyzed.
Risks
The structured data shows only one award criterion per lot, while the XML notice suggests all three criteria (technical...
Structured data marks 'isEuFunded: true', but the XML notice says 'FundingProgramCode: no-eu-funds'. This may affect co...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Open procedure; maximum 8 lots can be bid
- Award criteria per lot: mix of technical quality, environmental criteria, and price (weights vary per lot)
Administrative
- Electronic submission via SILEX platform (www.conselleriadefacenda.es/silex)
Requirements may be incomplete.
Award Criteria
Lot 1
Lot 2
Lot 3
Lot 4
Lot 5
Lot 6
Lot 7
Lot 8
Buyer
Location
Santiago de Compostela, ESP
Website
Buyer profile
Identifier
Q6550006H
Activity
Health
Lots (8)
LOT-0001
Bevacizumab (intravenous)
Supply of Bevacizumab intravenous formulation for day hospital administration.
EUR 54M
Estimated value
Location
Duration
Category
Award Criteria
Deadline
Award details
Calidad técnica
Value note
Show original TED data
Original lot title
Bevacizumab vía intravenosa
Original TED description
Bevacizumab vía intravenosa
LOT-0002
Eculizumab (intravenous)
Supply of Eculizumab intravenous formulation for day hospital administration.
EUR 54M
Estimated value
Location
Duration
Category
Award Criteria
Deadline
Award details
Criterios Medioambientales
Value note
Show original TED data
Original lot title
Eculizumab vía intravenosa
Original TED description
Eculizumab vía intravenosa
LOT-0003
Infliximab (intravenous)
Supply of Infliximab intravenous formulation for day hospital administration.
EUR 54M
Estimated value
Location
Duration
Category
Award Criteria
Deadline
Award details
Oferta económica (precio unitario)
Value note
Show original TED data
Original lot title
InBliximab vía intravenosa
Original TED description
InBliximab vía intravenosa
LOT-0004
Natalizumab vía intravenosa
Natalizumab vía intravenosa
EUR 54M
Estimated value
Location
Duration
Category
Award Criteria
Award details
Calidad técnica
LOT-0005
Rituximab vía intravenosa
Rituximab vía intravenosa
EUR 54M
Estimated value
Location
Duration
Category
Award Criteria
Award details
Criterios Medioambientales
LOT-0006
Tocilizumab vía intravenosa
Tocilizumab vía intravenosa
EUR 54M
Estimated value
Location
Duration
Category
Award Criteria
Award details
Oferta económica (precio unitario)
LOT-0007
Trastuzumab vía intravenosa
Trastuzumab vía intravenosa
EUR 54M
Estimated value
Location
Duration
Category
Award Criteria
Award details
Calidad técnica
LOT-0008
Ustekinumab vía intravenosa
Ustekinumab vía intravenosa
EUR 54M
Estimated value
Location
Duration
Category
Award Criteria
Award details
Criterios Medioambientales
Procurement Details
- Publication date
- 09 Jul 2026
- Languages
- Spanish
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 477960-2026
Documents (2)
Similar tenders
Poland – Furniture – DZP.242.306.2026 Sukcesywny zakup wyposażenia meblowego wraz z dostawą, montażem i ustawieniem w pomieszczeniach Uniwersyteckiego Szpitala Klinicznego we Wrocławiu
Greece – Installation of cable laying – Προμήθεια υλικών και πλήρης κατασκευή της εναέριας Γ.Μ. 400kV ΚΥΤ ΝΕΑΣ ΣΑΝΤΑΣ – ΚΥΤ ΦΙΛΙΠΠΩΝ
Germany – Installation of doors and windows and related components – Tischlerarbeiten - Innentüren DIN 18355
Czechia – Portable computers – OPST – Konektivita, HW, SW, vybavení středních škol v Ústeckém kraji – SPŠ ÚL, Resslova – Koncové prvky II.
Poland – Electricity, heating, solar and nuclear energy – Świecka Grupa Zakupowa. Dostawa energii elektrycznej w okresie od 01.01.2027r. do 31.12.2027r.
Croatia – Restructuring work – Izvođenje radova na rekonstrukciji i dogradnji Konjičkog centra
Opportunity Score
Why this score?
Opportunity
70 / 100
Complexity
60 / 100
Risk factors
The structured data shows only one award criterion per lot, while the XML notice suggests all three criteria (technical...
Structured data marks 'isEuFunded: true', but the XML notice says 'FundingProgramCode: no-eu-funds'. This may affect co...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications